Neurometrix Inc (NURO)

[x1power]

Did GSK just plain cover their options, as to acquiring a mechanical/electro substitute for opiates crisis?

Where is PR of new hires for marketing in USA O-T-C approach to potential retail vendors? Would O-T-C not be a direct affront (competitive-wise) to their potential medical provider in-house (office prescribed) sales?
Big deal with NURO device is cloud communication with medical provider, as to texting use info as o adjusting pain control regime.
How can both just potential patient buying over-counter to avoid paying office call fee work, when NURO is different from competitors already on the O-T-C shelves, in that professional medical provider can monitor electronically and advise device user via cloud?

Big pharma also would not be happy to have USA product to fight pain, etc. w/o medication? Also, talk on MJ boards that a few puffs or consumable MJ ingestion works wonders for sleep and daily routine stress/plain relief.

And, no NURO talk of when this all is to happen.

Further, no discussion by NURO of what new R&D costs to them specifically involves in upgrading their Quell.

Would we not need repeated 'new funding' sources to get all this done?
And, what does that mean for stock price?

Lots of stuff behind-the-curtain to consider herein, yet I do like the concept and GSK involvement. ANyone to comment on above?